Helix BioPharma Announces Change of Auditor
2013年7月12日 - 8:53PM
Marketwired
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (the "Company" or
"Helix"), a biopharmaceutical company developing drug candidates
for the prevention and treatment of cancer, today announced that it
has initiated the process of changing Helix's auditor from KPMG LLP
("KPMG") to BDO Canada LLP ("BDO"). The change will be effective as
of the completion of the audit for the Helix's 2013 fiscal year by
KPMG and a transition period has already commenced.
"The voting result regarding the appointment of auditors at the
2012 AGM was a clear signal for this change," said Robert Verhagen,
CEO. "We are looking forward to working with BDO during the
transition period and in the future."
In accordance with National Instrument 51-102 ("NI 51-102"),
Helix sent a Change of Auditor Notice to each of KMPG and BDO on
June 21, 2013 and on June 24 and 28, 2013 Helix received copies of
the letters from KPMG and BDO, respectively, addressed to the
Ontario Securities Commission (the "OSC"), as required by NI
51-102. A copy of the Change of Auditor Notice, together with a
copy of the letters from each of KPMG and BDO addressed to the OSC,
have now been filed under Helix's profile on SEDAR and delivered to
each of KPMG and BDO, all in compliance with NI 51-102.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and
Uncertainties
This news release contains certain forward-looking statements
and information (collectively, "forward-looking statements") within
the meaning of applicable Canadian securities laws, including,
without limitation, that the change of auditors will occur and that
such change will occur on the anticipated timelines.
Forward-looking statements are intended to provide information
about management's current plans and expectations regarding future
operations.
Although Helix believes that the expectations reflected in such
forward-looking statements are reasonable, such statements involve
risks and uncertainties that may cause actual results or events to
differ materially from those anticipated and no assurance can be
given that these expectations will be realized, and undue reliance
should not be placed on such statements. Risk factors that could
cause actual results or events to differ materially from the
forward-looking statements include, without limitation, those risks
and uncertainties affecting the company as more fully described in
Helix's most recent Annual Report, including under the headings
"Forward-Looking Statements" and "Risk Factors", filed with the
Canadian Securities Administrators at www.sedar.com (together, the
"Helix Risk Factors"). Certain material factors or assumptions are
applied in making the forward-looking statements, including,
without limitation, that the change of auditors will occur and that
such change will occur on the anticipated timelines and the Helix
Risk Factors will not cause Helix's actual results or events to
differ materially from the forward-looking statements.
Forward-looking statements and information are based on the
beliefs, assumptions and expectations of Helix's management on the
date of this news release, and Helix does not assume any obligation
to update any forward-looking statement or information should those
beliefs, assumptions or expectations, or other circumstances
change, except as required by law.
Investor Relations: Helix BioPharma Corp. Tel: 905
841-2300 Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
過去 株価チャート
から 5 2024 まで 6 2024
Helix BioPharma (TSX:HBP)
過去 株価チャート
から 6 2023 まで 6 2024